Arthur T. Sands - 10 Feb 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: President, CEO, Director
Issuer ticker: NRIX
Reported as of: 10 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Feb 2026, 17:43:09 UTC
Prior SEC filing: 13 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Daniel Burbach, as Attorney-in-Fact for Arthur T. Sands

Filing notes and source

Key filing fact

Arthur T. Sands filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 10 Feb 2026.

Key facts

This page summarizes Arthur T. Sands's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Feb 2026, 17:43.

Change

Previous filing in this sequence was filed on 13 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001134106 Primary reporting owner

SANDS ARTHUR T

Relationship: President, CEO, Director
Address: C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Arthur T. Sands
Signature date: 10 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +562,500
Change %
Price: $0.000000
Shares after: 562,500
Date: 10 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 562,500
Exercise price: $16.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.